A healthcare tracking poll finds unhappiness aimed at the drug industry for high drug prices while more Americans are warming up to the idea of a national health plan; a study says opioid overdose deaths are undercounted by as much as 35%; whole-genome sequencing may not drive up downstream medical costs, but questions about its use remain.
A poll from the Kaiser Family Foundation found that 72% of Americans think the drug industry has too much influence in Washington, Kaiser Health News reported. In addition, more people are taking to the notion of a national health plan. Overall, 59% said they supported it; that percentage rose to 75% if such a plan was presented as 1 option among others to choose from.
Standards for how to investigate and report on overdoses vary widely across states and counties, NPR reported, leading to an undercounting of opioid overdose deaths. The country is undercounting opioid-related overdoses by 20% to 35%, according to a recent study in the journal Addiction. Local coroners and medical examiners send data from death certificates to state offices, eventually landing at the CDC, which reported that more than 42,000 people died from opioid-related overdoses in 2016. The author of the study said the real number is likely closer to 50,000.
Will whole-genome sequencing drive up downstream costs? A study reported in STAT indicated that could be a possibility, although questions remain. Healthy volunteers who had genome sequencing incurred slightly higher medical costs of $3670, on average, compared with $2989 for those who had just a basic family medical history. Some issues raised include how providers who are not experienced in genetics or statistics will understand the results without practicing defensive medicine, as well as the nation’s shortage of genetic counselors.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More